Mar 21, 2020

Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum Galectin-3 level

Journal of Diabetes Investigation
Shizhan MaQingqing Yin


Galectin-3 (Gal3) contributes to insulin resistance, inflammation, and obesity, the three risk factors for mild cognitive impairment (MCI) in type 2 diabetes mellitus (T2DM) patients. 134 hospitalized T2DM patients were assessed by the Montreal Cognitive Assessment (MoCA) method and divided into 65 MCI and 69 controls. Levels of variables Gal3 and Aβ42 were investigated in relationship with cognitive function in both T2DM patients with MCI and high-fat diet (HFD)/streptozotocin (STZ) induced T2DM rats. A significant higher level of serum Gal3 and lower level of plasma Aβ42 (all P < 0.05) were found in MCI T2DM group as compared to non-MCI T2DM control. Partial correlation analysis showed that Gal3 is negatively correlated with both MMSE score (r=-0.51, P < 0.01) and MoCA score (r=-0.47, P < 0.001) after adjustment for HbA1c, HOMA-IR and Aβ42 in total T2DM patients, with stronger effect seen in MCI T2DM group after further analysis with MCI strata. Simple logistic regression model demonstrated that Gal3 and Aβ42 are significantly associated with MCI T2DM patients after adjustment with the covariates sex, age, BMI, HbA1c, HOMA-IR, and anti-diabetics drugs. Serum and brain Gal3 levels were significantly increased in HFD/STZ diabet...Continue Reading

  • References38
  • Citations


  • References38
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Glycosylated hemoglobin A
Montreal Cognitive Assessment
Mild Cognitive Disorder
Amyloid beta-protein (1-42)
Galectin 3

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.